SHANGPHAR ADR : ShangPharma Opens New Pilot Plant Facility
01/14/2011| 04:30am US/Eastern
Recommend:
ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"), a
leading China-based pharmaceutical and biotechnology research and
development outsourcing company, today announced commencement of
operations on the initial phase of production at the Company's Fengxian
facility. This new multi-purpose pharmaceutical development and cGMP
manufacturing facility is located in Fengxian in the suburbs of
Shanghai, China. The state-of-the-art facility will operate as a wholly
owned subsidiary of the Company under the name of China Gateway
Pharmaceutical Development Co. Ltd., and will allow the Company to
expand its service offering to process research and development,
formulation research and development, analytical method development and
validation, and cGMP manufacturing of intermediates and APIs.
This project represents ShangPharma's growing capabilities in cGMP
manufacturing. To date, ShangPharma has successfully developed client
projects from the early discovery phase to the provision of materials
for GLP Toxicology and Phase I Clinical trials. With the newly added
capacity in the Fengxian plant, the Company will be able to support its
clients' projects all the way through Phase II and into Phase III
development, depending on scale. The Company may further expand its
manufacturing facilities if it experiences strong demand for commercial
manufacturing of FDA- or EMEA-approved drugs.
The Fengxian facility includes a pilot plant that has six separate bays
with reactor capacities ranging from 200 to 3,000 liters and other
specialty bays with reactor capacities ranging from 50 to 2000 liters
for high temperature, cryogenics, highly toxic and pressurized
reactions, including hydrogenation. There are also two clean room suites
rated at Class 100,000 for isolation, 10 kilo-labs suites for
bothnon-cGMP and cGMP manufacturing as well as a large research and
development laboratory for analytical, formulation and process
development activities. In addition, there are separate buildings for
utilities, materials management, warehouse storage and waste water
treatment with room for further expansion to support commercial
manufacturing activities.
Part of the new facility is dedicated to analytical support. Testing of
raw materials, intermediates and final products will be carried out at
the site. An independent quality assurance department ensures that
materials are manufactured in accordance with cGMP requirements and that
established standard operating procedures are followed.
ABOUT SHANGPHARMA CORPORATION
ShangPharma Corporation is a leading China-based contract research
organization providing high-quality and cost-effective services for the
pharmaceutical and biotechnology industry. It offers a broad range of
high-quality, integrated services across the drug discovery and
development process to help international and Chinese pharmaceutical and
biotechnology companies discover and develop novel drug candidates
efficiently. ShangPharma's services consist of discovery chemistry,
discovery biology and preclinical development, pharmaceutical
development and biologics services. For more information, please visit www.shangpharma.com.
ShangPharma Corporation
Lan Xie, VP of Finance and Operations
IR@shangpharma.com
or
Christensen
In
New York
Kimberly Minarovich, +917-533-3268
kminarovich@christensenir.com
or
In
Hong Kong
Tip Fleming, +852-9212-0684
tfleming@christensenir.com
© Business Wire 2011
Recommend :
